ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

ClinicalTrials.gov ID: NCT06386146

Public ClinicalTrials.gov record NCT06386146. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Study identification

NCT ID
NCT06386146
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Enrollment
144 participants

Conditions and interventions

Conditions

Interventions

  • JAB-30355 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 23, 2024
Primary completion
Dec 31, 2026
Completion
Jun 30, 2027
Last update posted
Jan 21, 2026

2024 – 2027

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Research Site Denver Colorado 80218 Recruiting
Research site Lake Mary Florida 32771 Recruiting
Research site St Louis Missouri 63110 Recruiting
Research site Canton Ohio 44718 Terminated
Research site Cleveland Ohio 44195 Recruiting
Research Site Nashville Tennessee 37203 Recruiting
Research site Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06386146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 21, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06386146 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →